• Agenus flagged new retrospective data that uses Noetik’s AI model to predict which patients may benefit from its investigational botensilimab and balstilimab immunotherapy combination.
• Results will be presented May 30, 2026 at the ASCO annual meeting, based on pretreatment routine tumor pathology images from 113 efficacy-evaluable patients in the C-800-01 Phase 1b trial.
• In microsatellite-stable metastatic colorectal cancer patients without active liver metastases, the model showed predictive value for both treatment response and survival, with supportive signals in ovarian cancer and sarcomas.
• The work targets a key commercial issue for the regimen, which has not been closely linked to standard biomarkers, by proposing an image-based approach that could support future patient selection if confirmed prospectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521604737) on May 21, 2026, and is solely responsible for the information contained therein.